We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




First-Of-Its-Kind Technology Platform Leverages Bacteriophages to Tackle Critical and Life-Threatening Infections

By HospiMedica International staff writers
Posted on 16 Jun 2023

The escalating global health crisis of antimicrobial resistance, referred to as 'the silent pandemic', is predicted by the World Health Organization (WHO) to account for 10 million deaths per year by 2050. More...

Recognized by the WHO as one of the top 10 global health threats to mankind, drug-resistant infections have already caused more than 5 million deaths worldwide. Now, a world-first technology platform that leverages the innate power of bacteriophages, viruses that infect and destroy bacteria, to eliminate critical and life-threatening infections marks a significant medical breakthrough for countering the global threat of antimicrobial resistance.

Bacteriophages, also called phages, are naturally occurring viruses that have been battling bacteria throughout evolution. They are capable of infiltrating and destroying bacterial colonies with unerring precision. While phages have been deployed in human treatments for over a century, their full medical potential remains untapped. PHIOGEN (Houston, TX, USA) has developed an innovative platform that capitalizes on the successes of personalized phage therapy. PHIOGEN is a spin-off company from Baylor College of Medicine’s TAILOR Labs (Houston, TX, USA), one of the United States' only academic phage therapy cores with a decade’s worth of revolutionary research related to bacteriophages. PHIOGEN’s innovative platform leverages the successes of personalized phage therapy. The platform empowers PHIOGEN to identify unique phages with targeted neutralizing abilities, evolve hyper-lytic phages to counter resistance and test them in high-throughput biological models. The result is cultivated antimicrobial solutions that successfully productize bacteriophages to enhance clinical outcomes.

PHIOGEN has developed the world's only bacteriophage mass capture device, allowing the company to undertake phage reconnaissance missions, and collect and filter billions of phages from their natural environments, thereby reducing sample collection time from four days to just under four hours. PHIOGEN’s proprietary first-of-its-kind technology platform can discover and screen naturally occurring bacteriophages on a large scale, identifying those with superior bacterial combat abilities. It can then facilitate biological changes to evolve these phages into antimicrobials capable of overcoming resistance. This enables the creation of treatments for large populations rather than individual patients. By refining nature's guardians, PHIOGEN has developed extraordinary phage treatments that have already successfully saved numerous lives in FDA-approved compassionate use cases.

“Nothing about our treatments is fabricated, it boils down to creating natural environments that mimic real-life infections, driving biological changes to create "super phages” against the superbugs,” said Amanda Burkardt, CEO at PHIOGEN. “As a result, we receive high-performing phage fighters that are trained and ready to deliver safe and effective treatments for clinical applications.”

“Our patented technique of evolving the natural fighting power of bacteriophages creates a new paradigm in phage therapy where natural lytic cocktails carry the same advantages as fully synthetic phage and can be used to treat entire patient populations,” added Burkardt.

Related Links:
PHIOGEN 
Baylor College of Medicine 


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Anesthesia Cart
UTGSU-333369-DKB
New
Pedicle Screw Platform
CREO DLX Stabilization System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.